Provenance Wealth Advisors LLC purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,222 shares of the specialty pharmaceutical company’s stock, valued at approximately $514,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. USA Financial Formulas bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth $25,000. Pension & Wealth Management Advisors Inc. purchased a new position in Jazz Pharmaceuticals in the third quarter worth $32,000. Ameritas Advisory Services LLC purchased a new position in Jazz Pharmaceuticals in the second quarter worth $47,000. Westpac Banking Corp bought a new position in Jazz Pharmaceuticals in the first quarter valued at $51,000. Finally, Elevation Wealth Partners LLC increased its stake in Jazz Pharmaceuticals by 156.4% in the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 158 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.
Analyst Ratings Changes
JAZZ has been the topic of a number of research reports. Robert W. Baird raised their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft lifted their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, August 26th. Barclays upped their price objective on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday. Citigroup began coverage on Jazz Pharmaceuticals in a research report on Wednesday, September 30th. They set a “buy” rating and a $325.00 price objective on the stock. Finally, Truist Financial raised their price objective on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $293.45.
View Our Latest Stock Analysis on JAZZ
Insider Buying and Selling at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the sale, the executive vice president directly owned 65,686 shares of the company’s stock, valued at $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the sale, the director owned 339,875 shares of the company’s stock, valued at approximately $73,358,620. The trade was a 1.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 101,121 shares of company stock valued at $24,858,332. Company insiders own 4.10% of the company’s stock.
Key Headlines Impacting Jazz Pharmaceuticals
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
- Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
- Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing
Jazz Pharmaceuticals Trading Down 3.1%
Shares of JAZZ opened at $227.32 on Friday. The firm has a market cap of $14.59 billion, a price-to-earnings ratio of 77.32, a PEG ratio of 0.47 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The firm has a 50 day moving average price of $229.71 and a 200-day moving average price of $217.40.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the prior year, the company earned $8.13 EPS. The firm’s revenue was up 10.4% on a year-over-year basis. As a group, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Articles
- Five stocks we like better than Jazz Pharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
